Endologix Inc. Announces Preliminary Fourth Quarter 2012 Revenues
1/7/2013 9:49:47 AM
IRVINE, Calif., Jan. 7, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2012. Endologix anticipates fourth quarter 2012 global revenue of approximately $29.2 million and full year 2012 global revenue of approximately $105.9 million, representing approximately 25% and 27% year-over-year growth, respectively. The preliminary results compare to previously issued guidance of $104-$106 million in global revenues for the full year 2012.
comments powered by